Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kaken Pharmaceutical Co Ltd (JP:4521)
TSE/TYO:4521
Holding JP:4521?
Track your performance easily
4521 Stock Chart & Stats
Day’s Range¥0 - ¥0
52-Week Range¥3,161.00 - ¥4,577.00
Previous Close¥4,461
Volume209.00K
Average Volume (3M)137.38K
Market Cap
¥168.71B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)9.3
Beta0.31
Next Earnings
Jan 31, 2025EPS EstimateN/A
Next Dividend Ex-Date
Mar 28, 2025Dividend Yield4.46%
Share Statistics
EPS (TTM)481.72
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume137,380
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥6,084.98Price Target Upside36.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.85% Mutual Funds
― Other Institutional Investors
94.42% Public Companies and
Individual Investors
4521 FAQ
What was Kaken Pharmaceutical Co Ltd’s price range in the past 12 months?
Kaken Pharmaceutical Co Ltd lowest stock price was ¥3161.00 and its highest was ¥4577.00 in the past 12 months.
What is Kaken Pharmaceutical Co Ltd’s market cap?
Currently, no data Available
When is Kaken Pharmaceutical Co Ltd’s upcoming earnings report date?
Kaken Pharmaceutical Co Ltd’s upcoming earnings report date is Jan 31, 2025 which is in 69 days.
How were Kaken Pharmaceutical Co Ltd’s earnings last quarter?
Kaken Pharmaceutical Co Ltd released its earnings results on Nov 08, 2024. The company reported ¥330.91 earnings per share for the quarter, beating the consensus estimate of N/A by ¥330.91.
Is Kaken Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Kaken Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Kaken Pharmaceutical Co Ltd pay dividends?
Kaken Pharmaceutical Co Ltd pays a Annually dividend of ¥75 which represents an annual dividend yield of 4.46%. See more information on Kaken Pharmaceutical Co Ltd dividends here
What is Kaken Pharmaceutical Co Ltd’s EPS estimate?
Kaken Pharmaceutical Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kaken Pharmaceutical Co Ltd have?
Kaken Pharmaceutical Co Ltd has 45,939,728 shares outstanding.
What happened to Kaken Pharmaceutical Co Ltd’s price movement after its last earnings report?
Kaken Pharmaceutical Co Ltd reported an EPS of ¥330.91 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.514%.
Which hedge fund is a major shareholder of Kaken Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4521
---
Kaken Pharmaceutical Co Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.78%
12-Months-Change
Fundamentals
Return on Equity
12.06%
Trailing 12-Months
Asset Growth
13.73%
Trailing 12-Months
Company Description
Kaken Pharmaceutical Co Ltd
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
---
Technical Analysis
Perrigo Company
―
Teva Pharmaceutical
―
Alkermes
―
GlaxoSmithKline
―
Kaken Pharmaceutical Co
―
Best Analysts Covering 4521
1 Year
1 Year Success Rate
0/0 ratings generated profit
1 Year Average Return
0.00%
initiated a buy rating 7 days ago
Copying Unknown Analyst's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
---